Enoblituzumab is an Fc-enhanced anti-B7-H3 mAb inducing antibody-dependent cellular cytotoxicity (ADCC)-mediated anti-tumor activity;243 phase I studies and a phase II prostate cancer study (NCT02923180) demonstrated favorable safety and efficacy. This evidence concerns the gene CD80 and neoplasm.